Di Caro V, Cho E, North HA, et al. Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer’s disease drug candidate CT1812. Alzheimer’s Dement. 2025; 11:e70119. https://doi.org/10.1002/trc2.70119
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics
Ophthalmology Times
By Emily Kaiser Maharjan
May 8, 2025
Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics Read More »
Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, announced today that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer’s disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH Alzheimer’s Disease Drug
Cognition Therapeutics’ Selected for Support by National Institute on Aging Read More »
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
